Akito Hata

2.6k total citations
117 papers, 1.7k citations indexed

About

Akito Hata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Akito Hata has authored 117 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pulmonary and Respiratory Medicine, 84 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Akito Hata's work include Lung Cancer Treatments and Mutations (84 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (31 papers). Akito Hata is often cited by papers focused on Lung Cancer Treatments and Mutations (84 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (31 papers). Akito Hata collaborates with scholars based in Japan, United States and Italy. Akito Hata's co-authors include Nobuyuki Katakami, Reiko Kaji, Shiro Fujita, Keisuke Tomii, Yukihiro Imai, Hiroshige Yoshioka, Tadashi Ishida, Akihiro Nishiyama, Jumpei Takeshita and Katsuhiro Masago and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Akito Hata

106 papers receiving 1.6k citations

Peers

Countries citing papers authored by Akito Hata

Since Specialization

Citations

This map shows the geographic impact of Akito Hata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akito Hata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akito Hata more than expected).

Fields of papers citing papers by Akito Hata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akito Hata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akito Hata. The network helps show where Akito Hata may publish in the future.

Co-authorship network of co-authors of Akito Hata

This figure shows the co-authorship network connecting the top 25 collaborators of Akito Hata. A scholar is included among the top collaborators of Akito Hata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akito Hata. Akito Hata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning 2025 ·Lung Cancer ·Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, Koji Haratani, Motohiro Tamiya, Takashi Kijima, Yuki Sato, Akito Hata, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Hisashi Tanaka, Naoki Furuya, Satoru Miura, (unknown), Shinya Sakata, Eisaku Miyauchi, Nobuyuki Yamamoto, Yasuhiro Koh, Hiroaki Akamatsu	1
2	Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor‐mutant non‐small cell lung cancer 2024 ·Cancer Medicine ·Akito Hata, Simon Fifer, Kazuo Hasegawa, Emiko Ando, (unknown), Michiko Takahashi, (unknown), (unknown), Akira Inoue	2
3	Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer 2024 ·Thoracic Cancer ·(unknown), (unknown), (unknown), Katsuya Hirano, (unknown), Akito Hata	3
4	Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L). 2024 ·Journal of Clinical Oncology ·Akito Hata, (unknown), (unknown), Yoshihito Kogure, Masahide Oki, Nobuyuki Katakami, Takashi Kijima, Toshihide Yokoyama, Hirotaka Matsumoto, Yuki Sato, Terufumi Kato, Shunichi Sugawara, Takeshi Sawada, Kenichi Yoshimura, Takashi Seto, Kazuhiko Nakagawa, (unknown), Nobuyuki Yamamoto	0
5	A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients 2024 ·Advances in Therapy ·Akito Hata, Shunichiro Iwasawa, Yusuke Sasaki, Kosei Tajima, Yasutaka Chiba	1
6	Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L) 2023 ·JTO Clinical and Research Reports ·Motoko Tachihara, Akito Hata, Takaaki Tokito, Satoshi Hara, (unknown), Satoru Miura, Yuki Sato, (unknown), Hiroshi Watanabe, (unknown), Ryo Toyozawa, Keiichi Ota, Kazushige Wakuda, Atsushi Nakamura, Mototsugu Shimokawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa	0
7	Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase 2023 ·Advances in Therapy ·Naoki Inui, Yukihiro Toi, Yasuto Yoneshima, Masahiro Morise, Akito Hata, Kaoru Kubota, Toshiaki Saeki, Tomohide Tamura	5
8	Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312) 2023 ·Lung Cancer ·Nobuyuki Katakami, Takashi Nishimura, (unknown), Akito Hata, Kazumi Nishino, Masahide Mori, Tomonori Hirashima, (unknown), Toshihiko Kaneda, Hisashi Ohnishi, Satoshi Morita, Yukimasa Hatachi	2
9	Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) 2022 ·Clinical Cancer Research ·Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa	22
10	Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial 2022 ·International Journal of Hematology ·Yoshinori Imamura, Kazunori Otsui, Kenta Mori, (unknown), (unknown), Akito Hata, Hidetoshi Hayashi, (unknown), Shinya Ohata, (unknown), Yohei Funakoshi, Masanori Toyoda, Kimikazu Yakushijin, Naomi Kiyota, Hiroshi Matsuoka, Hironobu Minami	4
11	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L) 2021 ·Clinical Lung Cancer ·Akira Hamada, Junichi Soh, Akito Hata, Kiyoshi Nakamatsu, Mototsugu Shimokawa, Yasushi Yatabe, Hiroyuki Oizumi, Masahiro Tsuboi, Hidehito Horinouchi, Ichiro Yoshino, Masayuki Tanahashi, Shinichi Toyooka, Morihito Okada, Hiroyasu Yokomise, Motohiro Yamashita, Yasumasa Nishimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Tetsuya Mitsudomi	12
12	Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study 2021 ·Radiotherapy and Oncology ·Yoko Tsukita, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Yuichiro Takeda, Hidetsugu Nakayama, (unknown), Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Eisaku Miyauchi, Keiichi Jingu, Hisatoshi Sugiura	30
13	MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L 2021 ·Annals of Oncology ·Kentaro Ito, Shinya Sakata, Kohei Otsubo, Atsushi Nakamura, Shunsuke Teraoka, N Matsumoto, Yoshimasa Shiraishi, Koji Haratani, Motohiro Tamiya, Satoshi Ikeda, Satoru Miura, Junko Tanizaki, Shota Omori, Hiroshige Yoshioka, Akito Hata, Hisako Yoshida, Nobuyuki Yamamoto, Kazuhiko Nakagawa	1
14	Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation 2021 ·Anticancer Research ·Hiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Eriko Murakami, (unknown), Toshio Shimokawa, Yasuhiro Koh, Nobuyuki Yamamoto	4
15	<p>A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</p> 2019 ·Cancer Management and Research ·Motoko Tachihara, Tatsunori Kiriu, Akito Hata, (unknown), Kyosuke Nakata, Tatsuya Nagano, Masatsugu Yamamoto, Kazuyuki Kobayashi, Hisashi Ohnishi, Nobuyuki Katakami, Yoshihiro Nishimura	5
16	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer 2019 ·Cancer Science ·Shinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, Masahiko Ando, Akito Hata, Haruyasu Murakami, Takahiro Kawakami, (unknown), Kenichi Yoshimura, T. Fujiwara, Azusa Tanimoto, Akihiro Nishiyama, Sachiko Arai, Koji Fukuda, Nobuyuki Katakami, Toshiaki Takahashi, Yoshinori Hasegawa, Tun Kiat Ko, S. Tiong Ong, Seiji Yano	28
17	Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study 2018 ·Clinical Lung Cancer ·Hiroaki Akamatsu, Yasuhiro Koh, Yuichi Ozawa, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Toshio Shimokawa, Nobuyuki Yamamoto	12
18	Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non–small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L) 2018 ·Clinical Lung Cancer ·Akito Hata, Nobuyuki Katakami, Mototsugu Shimokawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Kazuhiko Nakagawa	2
19	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer 2017 ·Molecular Cancer Therapeutics ·Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, Seiji Yano	47
20	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109) 2014 ·Lung Cancer ·Yoshihiro Hattori, Miyako Satouchi, (unknown), Yoshiko Urata, Tsutomu Yoneda, Masahide Mori, Takashi Nishimura, (unknown), Toru Kumagai, Fumio Imamura, Shiro Fujita, Reiko Kaji, Akito Hata, Motoko Tachihara, Satoshi Morita, Shunichi Negoro	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact